Physician profile
Erwin Villavert
NPI 1598987331
$757.17
in general payments reported to CMS, 2019-2025
16 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $153 · 2024: $358 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $166.23 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $76.77 | 2025 | Erleada |
| Eisai INC. | $69.95 | 2024 | |
| Teleflex LLC | $68.69 | 2024 | |
| Ferring Pharmaceuticals INC. | $39.52 | 2024 | Adstiladrin |
| Sun Pharmaceutical Industries INC. | $39.23 | 2024 | |
| Genentech USA, INC. | $34.97 | 2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $33.27 | 2022 | |
| Dendreon Pharmaceuticals LLC | $33.24 | 2024 | Provenge |
| Seagen INC. | $33.19 | 2022-2023 | Adcetris |
| Urovant Sciences INC | $31.22 | 2022 | |
| Amgen INC. | $30.78 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Tempus Ai, INC | $29.43 | 2024 | |
| Incyte Corporation | $25.95 | 2023 | Monjuvi, Pemazyre |
| Pfizer INC. | $23.42 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Villavert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.